The UK sits in an unusual position: a significant private cannabis medicine market, but a regulatory framework that still classifies the cannabis plant as having no therapeutic value. Understanding that tension — and where it goes next — is essential for anyone operating in or investing in the UK sector.
To understand the UK cannabis regulatory landscape, the starting point is the Misuse of Drugs Regulations 2001, which implements the Misuse of Drugs Act 1971 by dividing controlled substances into five schedules based on their accepted medical use and potential for harm.
The cannabis plant (Cannabis sativa L.) and cannabis resin remain Schedule 1 — the most restricted category, reserved for substances deemed to have no accepted medicinal use. Possession, supply or production without a Home Office licence is a criminal offence.
Cannabis-based medicinal products meeting the statutory definition — preparations of or containing cannabis, for human medicinal use — moved to Schedule 2 in November 2018. Specialist doctors may prescribe them; pharmacies may dispense them.
The result is a structural anomaly. A patient holding a valid prescription for a Schedule 2 CBMP is in legal receipt of a product derived from a Schedule 1 plant. The plant itself — and anyone cultivating or processing it without a Home Office Controlled Drug licence — remains in the most restricted category. This creates significant friction in domestic supply chain development and constrains the research pipeline.
Commercial operators wishing to cultivate, produce or supply cannabis in the UK — whether for pharmaceutical manufacture, research or any other purpose — require a Schedule 2 Controlled Drug (CD) licence from the Home Office Drugs and Firearms Licensing Unit. The licence is site-specific, activity-specific and subject to renewal. Application timelines range from six to 18 months; the process involves detailed security assessments, enhanced background checks on key personnel, and inspector visits to the proposed site.
Importantly, a Home Office CD licence does not authorise the commercial supply of medicines to patients — that requires a separate MHRA authorisation for each product. These two regulatory processes operate in parallel and are administered by different government departments, which multiplies both the timeline and the cost of bringing a cannabis medicine to market.
The November 2018 rescheduling decision, announced by the then Home Secretary Sajid Javid following two high-profile cases involving children with severe epilepsy, was widely characterised in media coverage as making medical cannabis "legal" in the UK. The reality was considerably more limited.
The statutory instrument moved cannabis-based medicinal products (defined as preparations of or containing cannabis, or cannabis resin, or cannabinol or a cannabinol derivative) from Schedule 1 to Schedule 2 and Schedule 4, depending on their THC content. Critically, it did not:
What it did achieve was the creation of a legal channel for specialist doctors to prescribe Schedule 2 and 3 cannabis-derived products imported from international suppliers, principally through a named-patient basis under the Medicines Act's 'specials' provisions. This laid the foundation for the private CBMP market that has subsequently grown substantially.
The UK cannabis medicine market divides cleanly between the NHS and private sectors — and the commercial dynamics of each are fundamentally different.
NHS England guidance on cannabis-based treatments has been cautious throughout the post-2018 period. The National Institute for Health and Care Excellence (NICE) has approved cannabis-based medicines in a limited set of specific indications — most notably Epidyolex for treatment-resistant epilepsy and Sativex for spasticity in multiple sclerosis — but has consistently noted insufficient clinical evidence to support broader prescribing.
The consequence is that NHS CBMP prescribing has remained modest, with approximately 20,000 patients receiving treatment through NHS channels as of 2025. The structural barriers are well-documented: prescribers face reputational and medicolegal risk when prescribing unlicensed products; clinical commissioning bodies resist funding treatments without NICE approval; and the absence of a licensed botanical cannabis product means there is no straightforward reimbursement pathway for flower or oil-based preparations.
The private CBMP market tells a different story. Operators including Curaleaf UK, Sapphire Medical Clinics, Lyphe Group and Mamedica have built clinical networks that collectively serve an estimated 100,000 patients, with the market valued at approximately £300–500 million as of 2025. This growth has occurred despite — or arguably because of — the NHS's caution: patients who cannot access treatment through the NHS have sought private clinic consultations and prescriptions at their own cost.
The private market model typically involves a specialist clinician consultation (in-person or telehealth), a prescription for a Schedule 2 CBMP, and fulfilment through a registered pharmacy. Product is predominantly imported from licensed manufacturers in Canada, the Netherlands, Denmark, Germany and Portugal. UK domestic manufacturing at commercial scale remains limited by the complexity of the Home Office licensing process.
A cannabis medicine that achieves a full marketing authorisation from the MHRA occupies an entirely different regulatory and commercial position than an unlicensed 'special'. Licensed medicines can be actively promoted to prescribers, may qualify for NHS formulary inclusion, and are not subject to the same import restrictions as unlicensed products.
The requirements for MHRA marketing authorisation are substantively the same as for any prescription medicine: a complete dossier of preclinical and clinical data demonstrating safety and efficacy; pharmaceutical-grade manufacture to UK-GMP standards; a risk management plan; and post-marketing surveillance commitments. For a cannabis medicine, this means investment in clinical trial programmes that are currently constrained by the Schedule 1 status of the plant itself — creating a circular regulatory problem that the rescheduling debate is partly aimed at resolving.
| Product | Active Compound | MHRA Status | Indication |
|---|---|---|---|
| Epidyolex | Cannabidiol (CBD) | Full marketing authorisation | Seizures associated with Lennox-Gastaut syndrome, Dravet syndrome |
| Sativex | THC + CBD (nabiximols) | Full marketing authorisation | Spasticity due to multiple sclerosis |
| Most CBMP flower/oils | Various cannabinoids | Unlicensed 'specials' | Prescribed off-label for chronic pain, PTSD, anxiety, neurological conditions |
The absence of a fully licenced botanical cannabis product is arguably the most significant structural constraint on the UK market's long-term growth potential. Without it, NHS prescribing will remain marginal and operator profitability will depend on private-pay volume — which, while real, is finite and concentrated in relatively affluent demographics.
The case for moving cannabis from Schedule 1 to Schedule 2 across the board — rather than only for specific CBMPs — centres on three principal arguments.
Schedule 1 status imposes exceptional barriers on academic and clinical researchers seeking to study cannabis. Universities and research institutions must obtain a Schedule 1 Home Office licence — a lengthy process — to work with the plant material. By comparison, Schedule 2 research access is significantly more straightforward. The consequence is a thin UK clinical evidence base, which in turn constrains NICE guidance and NHS prescribing. Advocates argue that rescheduling the plant is a prerequisite for generating the evidence that would support broader market access.
Full rescheduling would not automatically unlock commercial cultivation, but it would signal regulatory intent and could simplify the Home Office licensing process for domestic production. A more accessible domestic supply chain would reduce import dependency, improve product consistency, and potentially lower costs for patients.
As Germany, Denmark, and other EU markets develop more permissive frameworks for medical cannabis, the UK's restrictive regime risks making it an outlier — both as a market for patients and as a destination for capital investment in cannabis research and manufacturing.
The Labour government elected in July 2024 has shown no indication of pursuing rescheduling or any broader cannabis reform. Ministerial messaging from the Home Office and Department of Health and Social Care has focused on improving NHS access within the existing framework rather than structural regulatory change. No legislative proposals for rescheduling are before Parliament as of April 2026.
Before Brexit, the UK shared the European Medicines Agency's centralised authorisation procedure, meaning a medicine granted an EMA marketing authorisation was automatically authorised across all EU/EEA member states including the UK. That alignment ended with the UK's withdrawal from the EU's regulatory framework.
From 1 January 2021, the MHRA became the sole medicines regulatory authority for Great Britain (England, Scotland and Wales). Companies that hold or seek EMA authorisation for a cannabis-based medicine must now conduct a separate MHRA application process to access the UK market. For smaller operators, this doubles the regulatory burden and effectively prices them out of the UK unless the commercial opportunity justifies standalone investment in a parallel regulatory programme.
The practical consequence for the cannabis sector is that the UK and EU medicinal cannabis markets are diverging in their product landscapes. Medicines that achieve EMA approval do not automatically carry UK licence status; products developed specifically for the UK MHRA pathway may not qualify for EU mutual recognition. Over time, this regulatory divergence risks creating a two-tier product environment that disadvantages UK patients relative to their continental counterparts.
For operators and investors approaching the UK market in 2026, the following structural realities should frame commercial planning.
Approximately 100,000 patients, an estimated £300–500 million market value, and multiple operators now demonstrating repeat-prescription retention — the UK private sector is not speculative. It is a functioning, growing healthcare market. The entry barriers for clinical network operators are principally capital, medical staffing and regulatory compliance rather than demand uncertainty.
The gateway to NHS formulary inclusion and meaningful reimbursement is a fully MHRA-licenced cannabis medicine. Investment in the clinical programme required to achieve that is substantial — but it represents the only credible path to NHS scale. Operators positioning for NHS market access should be investing in or partnering on clinical trial programmes now.
Most CBMP product supplied to UK patients is imported. Import logistics for Schedule 2 controlled drugs are complex, expensive and subject to periodic supply chain disruption. Operators with the scale to justify a UK domestic manufacturing licence — or a third-party manufacturing agreement with a UK-licenced producer — can build a meaningful cost and supply security advantage.
There is no credible near-term risk of the UK reversing its 2018 CBMP prescribing change. The private market exists within a legal framework that has bipartisan political support at the level of patient access. The risk is not reversal — it is stasis: a framework that permits private market growth but does not evolve quickly enough to unlock NHS prescribing at meaningful scale.
26–27 May · The Barbican, London. UK regulatory policy, investor panels and cross-jurisdictional market analysis — with the senior professionals shaping the European cannabis sector.
